Skip to main content

Besivance Side Effects

Generic name: besifloxacin ophthalmic

Medically reviewed by Last updated on Jul 29, 2022.

Note: This document contains side effect information about besifloxacin ophthalmic. Some of the dosage forms listed on this page may not apply to the brand name Besivance.

For the Consumer

Applies to besifloxacin ophthalmic: ophthalmic suspension

Side effects requiring immediate medical attention

Along with its needed effects, besifloxacin ophthalmic (the active ingredient contained in Besivance) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking besifloxacin ophthalmic:

Less common

  • Blurred vision
  • eye pain
  • itching of the eye
  • red, sore eyes
  • swelling of the eye or eyelid

Side effects not requiring immediate medical attention

Some side effects of besifloxacin ophthalmic may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

For Healthcare Professionals

Applies to besifloxacin ophthalmic: ophthalmic suspension


Common (1% to 10%): Conjunctival redness, blurred vision, eye pain, eye irritation, eye pruritus, conjunctivitis, bacterial conjunctivitis

Uncommon (0.1% to 1%): Eyelid edema, conjunctival edema, corneal infiltrates, punctate keratitis, eye discharge, conjunctival hemorrhage, conjunctival disorder, dry eye, limbal hyperemia, conjunctival hyperemia, viral conjunctivitis, ocular hyperemia, reduced visual acuity, eyelid erythema, keratoconjunctivitis sicca, corneal staining, eyelid margin crusting

Postmarketing reports: Corneal deposits, corneal disorders, corneal edema, corneal opacity, corneal striae, eye edema, foreign-body sensation in eyes, increased lacrimation, ocular discomfort, photophobia, corneal dystrophy, anterior chamber disorder, blepharitis, corneal pigmentation, corneal scar, corneal thickening, eye inflammation, eye swelling, glare, halo vision, meibomian gland dysfunction, strabismus, ulcerative keratitis, visual impairment, endophthalmitis, hypopyon, corneal flap complication, diffuse lamellar keratitis, eye burn, eye injury, foreign body in eye, increased intraocular pressure, abnormal visual acuity test[Ref]

Nervous system

Common (1% to 10%): Headache

Postmarketing reports: Dizziness, dysgeusia, presyncope[Ref]


Uncommon (0.1% to 1%): Otitis media, ear infection

Postmarketing reports: Off-label use, impaired healing, medication residue, edema, drug ineffective (including for unapproved indication), gait disturbance, malaise, peripheral edema, pyrexia, candidiasis, staphylococcal infection, inappropriate schedule of drug administration, incorrect dose administered, incorrect drug dose form administered[Ref]


Uncommon (0.1% to 1%): Sinusitis, nasopharyngitis, upper respiratory tract infection, pharyngolaryngeal pain, nasal congestion, respiratory tract congestion, asthma, cough

Postmarketing reports: Dry throat, dyspnea, throat tightness[Ref]


Uncommon (0.1% to 1%): Depression

Postmarketing reports: Disorientation, insomnia[Ref]


Postmarketing reports: Increased blood pressure, endothelial dysfunction[Ref]


Postmarketing reports: Cold sweat, madarosis, photosensitivity reaction[Ref]


Postmarketing reports: Diarrhea, dysphagia, frequent bowel movements, gingival pain, glossodynia, mucous stools, nausea, sensitivity of teeth[Ref]


Postmarketing reports: Instillation site pain[Ref]


Postmarketing reports: Increased blood glucose, hypokalemia[Ref]


Postmarketing reports: Muscle spasm[Ref]


1. Cerner Multum, Inc. "Australian Product Information." O 0

2. "Product Information. Besivance (besifloxacin ophthalmic)." Bausch and Lomb (2009):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.